Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 15, 2015 - Issue 3
Submit an article Journal homepage
443
Views
41
CrossRef citations to date
0
Altmetric
Review

Building a roadmap for developing combination therapies for Alzheimer’s disease

Daniel PerryAlliance for Aging Research, Washington, DC, USA
,
Reisa SperlingHarvard Medical School Brigham and Women’s Hospital, Boston, MA, USA
,
Russell KatzUS FDA Retired, San Diego, CA, USA
,
Donald BerryMD Anderson Cancer Center, Houston, TX, USA
,
David DiltsOregon Health and Science University, Portland, OR, USA
,
Debra HannaCritical Path Institute, Tucson, AZ, USA
,
Stephen SallowayBrown University Butler Hospital, Providence, RI, USA
,
John Q TrojanowskiDepartment Pathol and Lab Med, University of Pennsylvania, School of Medicine, Alzheimers Dis Core Ctr, Ctr Neurodegenerat Dis Res, Inst Ageing, Philadelphia, PA, USA
,
Chas BountraUniversity of Oxford, Headington, UK
,
Michael KramsJanssen Pharmaceuticals, Philadelphia, PA, USA
,
Johan LuthmanEisai, Philadelphia, PA, USA
,
Steven PotkinUniversity of California Irvine, Irvine, CA, USA
,
Val GribkoffElan, South San Francisco, CA, USA
,
Robert TempleUS FDA, Silver Spring, MD, USA
,
Yaning WangUS FDA, Silver Spring, MD, USA
,
Maria C CarrilloAlzheimer’s Association, Chicago, IL, USA
,
Diane StephensonCritical Path Institute, Tucson, AZ, USA
,
Heather SnyderAlzheimer’s Association, Chicago, IL, USA
,
Enchi LiuJanssen Pharmaceuticals, South San Francisco, CA, USA
,
Tony WareEli Lilly, Indianapolis, IN, USA
,
John McKewNational Institutes of Health, Bethesda, MD, USA
,
F Owen FieldsPfizer, Philadelphia, PA, USA
,
Lisa J BainPhiladelphia, PA, USA
&
Cynthia BensAlliance for Aging Research, Washington, DC, USACorrespondence[email protected]
 show all
Pages 327-333 | Published online: 23 Feb 2015

References

  • Stephenson D, Perry D, Bens C, et al. Charting a path toward combination therapy for Alzheimer’s disease. Available from: http://act-ad.org/wp-content/uploads/2014/05/Combination-therapy-for-AD_final-2.pdf 2012
  • Food and Drug Administration. Guidance for industry: enrichment strategies for clinical trials to support approval of human drug and biological products. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf 2012. [Last accessed 18 July 2013]
  • Food and Drug Administration. Draft guidance for industry. Alzheimer’s disease: developing drugs for the treatment of early stage disease. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf 2013. [Last accessed 24 February 2013]
  • Food and Drug Administration. Guidance for industry: Codevelopment of two or more unmarketed investigational drugs for use in combination. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf 2010. [Last accessed 13 April 2014]
  • Jack CRJr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:119-28
  • Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network. N Engl J Med 2012;367:795-804
  • Jack CRJr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-16
  • Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 2012;336:1511-13
  • Kamboh MI, Demirci FY, Wang X, et al. Genome-wide association study of Alzheimer’s disease. Trans Psychiatry 2012;2:e117
  • Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 2013;153:707-20
  • Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100
  • Bohrmann B, Caruso A, Tanghe A, et al. Combination therapy with Gantenerumab and BACE inhibitor accelerates amyloid lowering: New paradigm for treatment of Alzheimer’s disease? In: The 11th International Conference on Alzheimer’s & Parkinson’s Diseases. Florence, Italy; 2013
  • TRAIN. The research acceleration and innovation network. Available from: http://train.fastercures.org/about/

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.